These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

172 related articles for article (PubMed ID: 2143235)

  • 1. The effect of thromboxane receptor blockade versus thromboxane synthase inhibition on canine arterial graft patency.
    Bech FR; Cronenwett JL; McDaniel MD; Ogletree ML; Freeman DH
    J Vasc Surg; 1990 Aug; 12(2):119-25. PubMed ID: 2143235
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of a selective thromboxane synthase inhibitor on arterial graft patency and platelet deposition in dogs.
    McDaniel MD; Huntsman WT; Miett TO; Cronenwett JL
    Arch Surg; 1987 Aug; 122(8):887-92. PubMed ID: 2957981
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Combined thromboxane A2 synthetase inhibition and receptor blockade are effective in preventing spontaneous and epinephrine-induced canine coronary cyclic flow variations.
    Yao SK; Rosolowsky M; Anderson HV; Golino P; NcNatt JM; De Clerck F; Buja LM; Willerson JT
    J Am Coll Cardiol; 1990 Sep; 16(3):705-13. PubMed ID: 2143767
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Endogenous prostaglandin endoperoxides and prostacyclin modulate the thrombolytic activity of tissue plasminogen activator. Effects of simultaneous inhibition of thromboxane A2 synthase and blockade of thromboxane A2/prostaglandin H2 receptors in a canine model of coronary thrombosis.
    Golino P; Rosolowsky M; Yao SK; McNatt J; De Clerck F; Buja LM; Willerson JT
    J Clin Invest; 1990 Oct; 86(4):1095-102. PubMed ID: 2145320
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Endogenous prostaglandin endoperoxides may alter infarct size in the presence of thromboxane synthase inhibition: studies in a rabbit model of coronary artery occlusion-reperfusion.
    Golino P; Ambrosio G; Villari B; Ragni M; Focaccio A; Pace L; de Clerk F; Condorelli M; Chiariello M
    J Am Coll Cardiol; 1993 Feb; 21(2):493-501. PubMed ID: 8426016
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of antiplatelet agents in combination with endothelial cell seeding on small-diameter Dacron vascular graft performance in the canine carotid artery model.
    Schmidt SP; Hunter TJ; Falkow LJ; Evancho MM; Sharp WV
    J Vasc Surg; 1985 Nov; 2(6):898-906. PubMed ID: 2932562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The in vivo antiplatelet effects of thromboxane A2 synthase inhibitors are potentiated by simultaneous thromboxane A2/prostaglandin H2 receptor blockade.
    Golino P; Ambrosio G; Gresele P; Pascucci I; Ragni M; Russolillo E; Leproux GB; Chiariello M
    J Pharmacol Exp Ther; 1993 Aug; 266(2):511-7. PubMed ID: 8355187
    [TBL] [Abstract][Full Text] [Related]  

  • 8. The association of in vitro arachidonic acid responsiveness and plasma thromboxane levels with early platelet deposition on the luminal surface of small-diameter grafts.
    Freeman MB; Sicard GA; Valentin LI; Neuberger S; Mangino MJ; Anderson CB
    J Vasc Surg; 1988 Apr; 7(4):554-61. PubMed ID: 3127601
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Thromboxane (Tx) A2 receptor blockade and TxA2 synthase inhibition alone and in combination: comparison of anti-aggregatory efficacy in human platelets.
    Watts IS; Wharton KA; White BP; Lumley P
    Br J Pharmacol; 1991 Feb; 102(2):497-505. PubMed ID: 1826620
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Pharmacological characterization of FCE 27262, a combined thromboxane synthase inhibitor and PGH2/TXA2 receptor antagonist.
    Vaghi F; Colombo M; Pierucci L; Volpi D; Dho L; Ukmar G; Rosa B; Salvati P
    Drugs Exp Clin Res; 1993; 19(6):249-60. PubMed ID: 8013268
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Randomized trial of ridogrel, a combined thromboxane A2 synthase inhibitor and thromboxane A2/prostaglandin endoperoxide receptor antagonist, versus aspirin as adjunct to thrombolysis in patients with acute myocardial infarction. The Ridogrel Versus Aspirin Patency Trial (RAPT).
    Circulation; 1994 Feb; 89(2):588-95. PubMed ID: 8313547
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Intraarterial 9-beta-methyl carbacyclin improves canine polytetrafluoroethylene graft patency.
    Dacey LJ; Hees PS; Cronenwett JL
    J Vasc Surg; 1988 Jul; 8(1):21-7. PubMed ID: 3133494
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Novel angiotensin II AT(1) receptor antagonist irbesartan prevents thromboxane A(2)-induced vasoconstriction in canine coronary arteries and human platelet aggregation.
    Li P; Fukuhara M; Diz DI; Ferrario CM; Brosnihan KB
    J Pharmacol Exp Ther; 2000 Jan; 292(1):238-46. PubMed ID: 10604953
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A comparative evaluation of thromboxane receptor blockade, thromboxane synthase inhibition and both in animal models of arterial thrombosis.
    Salvati P; Dho L; Ukmar G; Vaga L; Rimoldi O; Patrono C
    J Pharmacol Exp Ther; 1994 Apr; 269(1):238-45. PubMed ID: 8169831
    [TBL] [Abstract][Full Text] [Related]  

  • 15. DTTX30, a combined thromboxane receptor antagonist and thromboxane synthetase inhibitor, prevents coronary thrombosis in anesthetized dogs.
    Guth BD; Müller TH
    Basic Res Cardiol; 1997 Jun; 92(3):181-90. PubMed ID: 9226103
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Effect of selective thromboxane synthetase inhibitor on vein grafts.
    Cargile M; Neyman SL; Hebeler RF; Askins R; O'Leary JP
    South Med J; 1987 Nov; 80(11):1355-9. PubMed ID: 3686135
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The effect of a combined thromboxane receptor- and synthesis-antagonist on platelet, fibrinogen and leucocyte uptake in ePTFE grafts: an experimental study in sheep.
    Lundell A; Bergqvist D; Leide S; Lindblad B; Ljungberg J
    Eur J Vasc Surg; 1992 May; 6(3):276-81. PubMed ID: 1534299
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Coronary vascular occlusion mediated via thromboxane A2-prostaglandin endoperoxide receptor activation in vivo.
    Fitzgerald DJ; Doran J; Jackson E; FitzGerald GA
    J Clin Invest; 1986 Feb; 77(2):496-502. PubMed ID: 3003161
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The effect of platelet inhibitory therapy on graft thromboresistance.
    Bearn PE; Bull H; Seddon AM; Marston A; McCollum CN
    Int J Exp Pathol; 1993 Oct; 74(5):425-31. PubMed ID: 8217777
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Combined arachidonic acid and ADP platelet inhibition maximizes patency of small-diameter vascular grafts.
    Valentin LI; Sicard GA; Freeman MB; Allen BT; McGoff MA; Anderson CB
    Surgery; 1988 Aug; 104(2):178-84. PubMed ID: 3135624
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.